• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名患有多发性硬化症的女性患者在接受β干扰素治疗后发生系统性硬化症。

The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.

作者信息

Powell A, Myles M L, Yacyshyn E

机构信息

Division of Rheumatology, Department of Medicine, Alfred Hospital, Melbourne, Victoria, Australia.

出版信息

Clin Rheumatol. 2008 Nov;27(11):1467-8. doi: 10.1007/s10067-008-0972-3. Epub 2008 Aug 15.

DOI:10.1007/s10067-008-0972-3
PMID:18704546
Abstract

We describe a 38-year-old patient with relapsing remitting multiple sclerosis who subsequently develops systemic sclerosis following a course of interferon B-1a injections. This rare association between MS and systemic sclerosis is interesting due to the added factor of beta interferon therapy prior to the onset of the systemic sclerosis. It is also important, as more patients are treated with interferon B-1a for multiple sclerosis, this is a potential association.

摘要

我们描述了一名38岁复发缓解型多发性硬化症患者，其在接受了一段时间的干扰素β-1a注射治疗后，随后发展为系统性硬化症。多发性硬化症与系统性硬化症之间的这种罕见关联很有意思，因为在系统性硬化症发病之前存在β干扰素治疗这一附加因素。这也很重要，因为越来越多的患者使用干扰素β-1a治疗多发性硬化症，这是一种潜在的关联。

相似文献

1
The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.一名患有多发性硬化症的女性患者在接受β干扰素治疗后发生系统性硬化症。
Clin Rheumatol. 2008 Nov;27(11):1467-8. doi: 10.1007/s10067-008-0972-3. Epub 2008 Aug 15.
2
Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.多发性硬化症患者接受肌肉内注射干扰素 β-1a 治疗后出现广泛荨麻疹。
Neurol Sci. 2011 Apr;32(2):309-11. doi: 10.1007/s10072-010-0432-0. Epub 2010 Oct 2.
3
A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.多发性硬化症中干扰素-β的疗效和耐受性的荟萃分析，整体及按药物和疾病类型。
Clin Ther. 2010 Oct;32(11):1871-88. doi: 10.1016/j.clinthera.2010.10.006.
4
Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.辛伐他汀治疗接受干扰素β1a 治疗的复发性缓解型多发性硬化症患者：一项双盲随机对照试验。
Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.
5
Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis.一名多发性硬化症患者在接受β-干扰素治疗后诱发系统性红斑狼疮。
Lupus. 2005;14(6):495-6. doi: 10.1191/0961203305lu2147xx.
6
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.奥瑞珠单抗与干扰素β-1a 治疗复发型多发性硬化症的疗效比较。
N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
7
Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study.
Mult Scler. 2015 Aug;21(9):1215-6. doi: 10.1177/1352458514562989. Epub 2015 Feb 6.
8
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.芬戈莫德与干扰素β-1a 在儿科多发性硬化症中的对比试验。
N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.
9
Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.皮下注射重组干扰素β-1a（利比）治疗复发缓解型多发性硬化症的研究聚焦
BioDrugs. 2005;19(5):323-5. doi: 10.2165/00063030-200519050-00005.
10
Psoriasis during interferon beta treatment for multiple sclerosis.多发性硬化症干扰素β治疗期间的银屑病。
Neurol Sci. 2010 Jun;31(3):337-9. doi: 10.1007/s10072-009-0184-x. Epub 2009 Nov 19.

引用本文的文献

1
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.醋酸格拉替雷和干扰素β-1a治疗多发性硬化症患者的不良副作用：病例报告的系统评价
Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340.
2
Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis.浆细胞样树突状细胞在系统性硬化症中作用的分子机制
Biology (Basel). 2023 Feb 10;12(2):285. doi: 10.3390/biology12020285.
3
Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis.

本文引用的文献

1
Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis.
Clin Exp Rheumatol. 2004 Sep-Oct;22(5):625-8.
2
Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders.
Br J Dermatol. 2002 Aug;147(2):385-6. doi: 10.1046/j.1365-2133.2002.48901.x.
3
Multiple sclerosis in the course of systemic sclerosis.系统性硬化症病程中的多发性硬化症。
Ann Rheum Dis. 2002 Feb;61(2):188. doi: 10.1136/ard.61.2.188.
4
非裔美国人系统性硬化症皮肤成纤维细胞中的差异 DNA 甲基化图谱。
Genes (Basel). 2021 Jan 20;12(2):129. doi: 10.3390/genes12020129.
4
The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.皮肤Ⅰ型干扰素在自身免疫和自身炎症性疾病中的作用。
J Immunol. 2020 Dec 1;205(11):2941-2950. doi: 10.4049/jimmunol.2000596.
5
Toll-like receptors in mediating pathogenesis in systemic sclerosis.Toll 样受体在系统性硬化症发病机制中的作用。
Clin Exp Immunol. 2020 Jul;201(1):14-24. doi: 10.1111/cei.13426. Epub 2020 Feb 21.
6
Safety, Tolerability, and Immunogenicity of Interferons.干扰素的安全性、耐受性和免疫原性。
Pharmaceuticals (Basel). 2010 Apr 20;3(4):1162-1186. doi: 10.3390/ph3041162.
7
Immunogenicity and other problems associated with the use of biopharmaceuticals.生物制药的免疫原性和其他问题。
Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318.
Immunopathogenesis of multiple sclerosis: the role of T cells.
Curr Opin Neurol. 1999 Jun;12(3):309-21. doi: 10.1097/00019052-199906000-00010.
5
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.干扰素α对弥漫性皮肤型硬皮病患者一年结局无改善作用：一项随机、双盲、安慰剂对照试验的结果
Arthritis Rheum. 1999 Feb;42(2):299-305. doi: 10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R.
6
Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.干扰素-γ治疗系统性硬化症：一项随机对照多中心试验
Br J Dermatol. 1998 Oct;139(4):639-48. doi: 10.1046/j.1365-2133.1998.02460.x.
7
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.美国关节炎及特定肌肉骨骼疾病患病率的估计。
Arthritis Rheum. 1998 May;41(5):778-99. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.
8
Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.异基因骨髓移植后复发的继发性急性髓系白血病对干扰素-α 2b免疫治疗的敏感性
Bone Marrow Transplant. 1997 Jun;19(11):1151-3. doi: 10.1038/sj.bmt.1700793.